GeneDx Holdings Approves Key Proposals at Annual Meeting

An announcement from GeneDx Holdings ( (WGS) ) is now available.

On June 18, 2025, GeneDx Holdings Corp. held its Annual Meeting of Stockholders, where key proposals were voted on and approved. The stockholders elected two Class I directors, Eli D. Casdin and Joshua Ruch, to serve three-year terms, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (WGS) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on GeneDx Holdings stock, see the WGS Stock Forecast page.

Spark’s Take on WGS Stock

According to Spark, TipRanks’ AI Analyst, WGS is a Neutral.

Despite strong earnings call momentum and strategic initiatives, GeneDx faces challenges with profitability and valuation, which weigh down the overall score. Continued revenue growth and strategic acquisitions are positive, but the stock’s technical position and valuation remain concerning.

To see Spark’s full report on WGS stock, click here.

More about GeneDx Holdings

GeneDx Holdings Corp. is a company incorporated in Delaware, focusing on providing genetic testing services and solutions. The company operates within the healthcare industry, specializing in genomic diagnostics and personalized medicine.

Average Trading Volume: 1,088,128

Technical Sentiment Signal: Sell

Current Market Cap: $1.91B

Learn more about WGS stock on TipRanks’ Stock Analysis page.